Ciprofibrate, a carcinogenic peroxisome proliferator, increases the phosphorylation of epidermal-growth-factor receptor in isolated rat hepatocytes

Eur J Biochem. 1993 Aug 1;215(3):903-6. doi: 10.1111/j.1432-1033.1993.tb18108.x.

Abstract

Ciprofibrate, a hypolipidaemic drug with carcinogenic and peroxisome-proliferation effects in rat liver, was found to increase the phosphorylation of epidermal-growth-factor receptor in 32P-labeled isolated rat hepatocytes. This effect was suppressed by protein-kinase-C inhibitors, and was accompanied by an almost complete inhibition of the receptor autophosphorylation normally induced by its ligand. However, in vitro experiments showed that protein-kinase-C phosphorylation of purified epidermal-growth-factor receptor was activated by ciprofibroyl-CoA, the acyl-CoA derivative of the drug, but not by the unmodified drug. Neither compound affected the ligand induction of epidermal-growth-factor-receptor autophosphorylation in isolated liver membranes. These results suggest that metabolically produced ciprofibroyl-CoA in liver cells would activate protein-kinase-C and produce changes in epidermal-growth-factor-receptor function.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acyl Coenzyme A / metabolism
  • Animals
  • Cells, Cultured
  • Clofibric Acid / analogs & derivatives*
  • Clofibric Acid / metabolism
  • Clofibric Acid / pharmacology
  • Enzyme Activation
  • ErbB Receptors / metabolism*
  • Fibric Acids
  • Hypolipidemic Agents / pharmacology*
  • Liver / drug effects*
  • Liver / metabolism
  • Microbodies / drug effects*
  • Phosphorylation
  • Protein Kinase C / metabolism
  • Rats

Substances

  • Acyl Coenzyme A
  • Fibric Acids
  • Hypolipidemic Agents
  • Clofibric Acid
  • ErbB Receptors
  • Protein Kinase C
  • ciprofibrate